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1 ABSTRACT 
 
 Chlamydia pneumoniae is a common obligate intracellular bacterium that causes upper and lower 
respiratory infections worldwide. C. pneumoniae infections are often persistent, and an acute infection 
may sometimes turn chronic. The treatment of acute infections can be problematic. Prolonged high-dose 
treatment with the currently available antibiotics is often needed to achieve clinical cure. In addition, 
more serious diseases such as atherosclerosis have recently been associated with chronic C. pneumoniae 
infection, which has proven to be extremely difficult to diagnose and impossible to treat with current 
antibiotics. Thus, new antichlamydial compounds are urgently needed.  
 
In the present study, new antichlamydial compounds were searched among natural and naturally derived 
compounds as well as from synthetic libraries. A library of structurally diverse natural compounds 
known to have a variety of health-promoting effects in humans was tested against C. pneumoniae. Also, 
a library of synthetic compounds was pre-screened in silico with a structural homolog of the potential C. 
pneumoniae target protein, in order to create a smaller and more active targeted library. Although 
antichlamydial compounds were found from both libraries, nature-based compounds showing higher 
activity. 
 
A new high-throughput screening (HTS) assay was developed for a more efficient search of 
antichlamydial compounds. After optimization of this partly automated time-resolved fluorometric 
immunoassay (TR-FIA), we were able to obtain results that were reliable, reproducible, and consistent 
with the two most widely used assays in chlamydia susceptibility testing, immunofluorescence staining 
(IF staining) and quantitative polymerase chain reaction (q-PCR).       
 
Although it has been known for a long time that C. pneumonia manipulates several host cell functions, 
details of these systems and the host cell signaling pathways related to this manipulation remain poorly 
characterized. Characterization of the host cell response to C. pneumoniae infection was one of the 
central purposes of this study. This response was monitored at both gene and protein levels. We were 
able to identify four different host cell proteins with significant differences in their expression caused by 
C. pneumoniae infection. All of these proteins were structural proteins, which supports earlier 
observations about the structural rearrangements that are required for a successful infection.    
 
At the genome level, we were able to identify hundreds of genes that were significantly affected by 
infection. In order to get more information out of the microarray data, we used a gene ontology (GO) 
classification, which groups genes according to their biological processes, cellular components, and 
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molecular functions. One set of potential drug target genes assumed to be important for C. pneumoniae 
infection was selected using GO classification data, and another set was selected using gene-wise 
analysis data, where data from infected cells is compared against control cell data. Expression changes 
of all target genes were confirmed with q-PCR, validated genes were silenced with the corresponding 
small interfering RNA (siRNA) molecule, and the effect of silencing on C. pneumoniae infection was 
monitored. Both methods revealed genes whose silencing reduced the number of C. pneumoniae 
particles, but GO-classified data proved to be more accurate and much more informative compared to 
gene-wise analysis data.   
 8
2 LIST OF ORIGINAL PUBLICATIONS 
 
I J. Alvesalo, H. Vuorela, P. Tammela, M. Leinonen, P. Saikku, P. Vuorela; Inhibitory effect of 
dietary phenolic compounds on Chlamydia pneumoniae in cell cultures. Biochemical 
Pharmacology 71 (2006) 735–741. 
II P. Tammela, J. Alvesalo, L. Riihimäki, S. Airenne, M. Leinonen, P. Hurskainen, K. Enkvist, and 
P. Vuorela; A novel time-resolved fluorometric immunoassay for screening of antichlamydial 
compounds. Analytical Biochemistry 333 (2004) 39-48. 
III J. Alvesalo, A. Siiskonen, M. Vainio, P. Tammela and P. Vuorela; Similarity based virtual 
screening: A tool for targeted library design. Journal of Medicinal Chemistry 49 (2006) 2353-
2356. 
IV J. Alvesalo, D. Greco, M. Leinonen, P. Vuorela and P. Auvinen; Microarray analysis of 
Chlamydia pneumoniae infected human epithelial cell line using gene ontology hierarchy 
(submitted). 
 
V K. Savijoki, J. Alvesalo, P. Vuorela, M. Leinonen and N. Kalkkinen; Proteomic Profiling of the 
Human Lung Cell Response to Chlamydia pneumoniae K7 Infection Using Two-Dimensional 
Difference Gel Electrophoresis and Mass Spectrometry (submitted). 
 
These publications are referred to in the text by their Roman numerals. 
Reprints were made with permission from the publisher. 
 9
3 LIST OF ABBREVIATIONS 
 
2D-DIGE             two-dimensional difference gel electrophoresis  
2D-PAGE            two-dimensional polyacrylamide gel electrophoresis 
DMSO             dimethyl sulfoxide  
EB elementary body   
GO gene ontology 
HTS high-throughput screening 
IF staining  immunofluorescence staining  
IFU inclusion-forming unit 
LPS lipopolysaccharide 
MIC minimum inhibitory concentration 
MIF microimmunofluorescence 
mRNA messenger RNA 
MS mass spectrophotometer 
NCE new chemical entity 
p.i. post infection 
PCR polymerase chain reaction 
q-PCR quantitative polymerase chain reaction 
RB reticulate body 
S/B signal-to-background ratio 
S/N signal-to-noise ratio 
siRNA small interfering RNA 
TR-FIA time-resolved fluorometric immunoassay 
 
Z’             screening window coefficient calculated from control sample data 
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4 INTRODUCTION 
 
The genus Chlamydia was established in 1966, when Moulder reported the bacterial nature of this 
pathogen (Moulder, 1966), and Chlamydia pneumoniae was separated as a distinct species in 1992. C. 
pneumoniae is primarily a human pathogen. It is a very common bacterium worldwide, and almost 
everyone is infected at some point of their life. Serological studies indicate that 60 to 70% of the adult 
population have antibodies against it, men being more often seropositive than women (Grayston, 1992). 
An acute C. pneumoniae infection causes upper and lower respiratory track infections, which can be 
severe in elderly people. C. pneumoniae infections are estimated to cause about 10% of all community-
acquired pneumonias and 5% of bronchitis and sinusitis cases in the adult population (Grayston, 2000).  
 
In some cases, acute C. pneumoniae infection can become chronic. The molecular mechanisms leading 
to chronic infections are poorly understood, but in vitro chronic infection can be achieved with various 
methods (Hogan et al., 2004). The C. pneumoniae life cycle provides ideal circumstances for the 
establishment of chronic infection. The elementary particle (EB), which is the infectious component of 
the bacterium, is metabolically inactive and therefore resistant to antibiotics. The intracellular form, i.e. 
the reticulate body (RB), is metabolically active and can be affected by some antibiotics, but eradication 
of the infection may be extremely difficult (Ekman et al., 1993b), and C. pneumoniae can be recovered 
from cell cultures even after 30-day antibiotic treatment (Kutlin et al., 2002). Over the last two decades, 
chronic C. pneumoniae infection has been associated with serious diseases such as atherosclerosis 
(Saikku et al., 1988). 
 
Acute C. pneumoniae infections can be treated with certain antibiotics (Kuo and Grayston, 1988) 
(Miyashita et al., 1997) (Roblin and Hammerschlag, 1998), but symptoms may recur or the infection 
may become persistent despite of these treatments (Hammerschlag et al., 1992b). And although there are 
problems concerning the treatment of acute C. pneumoniae infection, the situation with persistent 
infection is much worse. At the moment, there are no proper diagnostic methods or effective treatments 
for persistent C. pneumoniae infection. Incomplete eradication of persistent infection with the current 
antibiotics has been demonstrated in vitro (Kutlin et al., 1999), and the same problem can also be seen in 
large-scale clinical trials (Andraws et al., 2005) (Danesh, 2005).  
 
 
Drug development is an extremely complex and risky business. It takes a long time and costs a lot of 
money, and there is no guarantee of success. Lately, the pharmaceutical industry has invested heavily in 
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high-throughput screening (HTS) platforms and robots. These investments have not paid off  as 
anticipated (Schmid and Smith, 2004), since the majority of new drug candidates still fail in clinical 
trials, causing a decrease in the number of new chemical entities (NCE) (Graul and Prous, 2006). In 
order to improve the odds of success, a lot of effort has been put into the development of pre-clinical 
research methods. The availability of genome sequences for several pharmaceutically relevant organisms 
has opened up new possibilities for techniques that utilize this information, such as genomics and 
proteomics.  
 
Genomics and proteomics refer to studies that are directed towards all genes and proteins of an 
organism, respectively. Using these techniques, it is possible to study both normal and pathological 
stages on a genome-wide scale and to acquire valuable information that can be utilized in the early 
phases of the drug development process. Implementation of these approaches in the drug discovery 
process will undoubtedly speed up the development of safer, more effective, and better targeted 
therapeutic agents (Onyango, 2004). 
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5 REVIEW OF THE LITERATURE 
 
5.1 Chlamydia pneumoniae 
5.1.1 History 
The bacterium now known as C. pneumoniae was first isolated from the eye of a Taiwanese child back 
in 1965 and named TW-183. When the methods for cultivating chlamydia became available a few years 
later, it was noticed that TW-183 was similar, but not identical, to two already known chlamydia 
species, Chlamydia psittaci and Chlamydia trachomatis. Morphological comparisons indicated that TW-
183 bears closer resemblance to C. psittaci than C. trachomatis.  First suggestions about the role of TW-
183 as human pathogen were discovered 1985 (Saikku et al.) and more specific information started to 
build up and after the first respiratory isolation (AR-39) (Grayston et al., 1986). This isolation was done 
from a throat swab of a patient with pharyngitis in Seattle. It linked this pathogen, now named TWAR 
after the TW-183 and AR-39 isolates, to respiratory track infections and pneumonia. These findings led 
to a proposal for the establishment of a third species of the genus Chlamydia, called Chlamydia 
pneumoniae (Grayston et al., 1989).  
 
5.1.2  Development cycle 
C. pneumoniae is a gram-negative obligatory intracellular parasite of the eukaryotic cell, which has a 
unique intracellular development cycle inside the inclusion in the host cell cytoplasm  (Fig. 1). The 
development cycle of C. pneumoniae consists of two very different forms. The EB is a metabolically 
inactive form with a cystein-rich outer membrane. EB particles are about 0.3 μm in diameter, infective, 
and able to survive outside the host cell for a short time. The RB is larger, typically 1.0 μm in diameter, 
metabolically active, and able to replicate inside an inclusion in the host cell cytoplasm. C. pneumoniae 
infection begins when EB interact with the host cell, and the bacteria is taken up by the host cell via 
endocytosis. The details of this mechanism are unknown, but it is somehow related to the mannose 6-
phosphate/insulin-like growth factor 2 receptor (Puolakkainen et al., 2005). Inside the host cell, EBs are 
transported to the Golgi region, where they start to convert their endocytotic vesicle into an inclusion.  
 
Sphingomyelin and cholesterol are acquired from the host cell via an exocytic pathway, in a way that 
requires C. pneumoniae protein translation (Wolf and Hackstadt, 2001). 
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Figure 1. Developmental cycle of Chlamydia. Picture by Mirja Puolakkainen and electron microscopy 
by Laura Mannonen.  
 
These molecules are used as construction material for the growing inclusion, which is a requirement for 
successful intracellular development cycle. After 8 h, EBs start to differentiate into RBs inside the 
inclusion, and about 19 h post-infection (p.i.) RBs start to replicate through binary fission (Wolf et al., 
2000). This continues up to 48 h p.i., after which the first RBs start to convert back to EBs, but 
intermediate forms as well as replicating RBs can still be found (Fig. 2). At the end of the development 
cycle at 72 h p.i., inclusions contain increasing amounts of pear-shaped EBs, which are characteristic for 
the C. pneumoniae, but also a considerable amount of RBs (Chi et al., 1987). At about 90 h p.i., the 
intracellular cycle is complete, and the host cell has broken down in order to release the newly produced 
EBs into the extracellular space, where they can infect new cells.    
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Figure 2.  Electron microscopic images of the C. pneumoniae isolate K7 in HL cell culture at different 
stages of infection. Electron microscopy by Kari Lounatmaa.  
 
5.1.3 Structure 
 
The envelope of C. pneumoniae consists of two lipid layers, similarly to all gram-negative bacteria. Its 
outer membrane contains lipopolysaccharide (LPS), which is Chlamydia-specific and can be found in  
EBs and RBs. The inner layer contains peptidoglycan (Chopra et al., 1998), which usually plays an 
important structural role in gram-negative bacteria, but in Chlamydia its amount is too small to 
participate significantly in the maintenance of the structural integrity of the membrane. Regardless of 
this, Chlamydia particles are quite strong. This rigidity and osmotic stability is thought to originate from 
the covalent sulphur bridges that are formed between cysteine-rich proteins in the outer membrane 
complex. This complex consist mostly of 40 kDa major outer membrane protein (MOMP) (Caldwell et 
al., 1981), 60 kDa cysteine-rich outer membrane protein (omp2) (Newhall et al., 1982), 12.5 kDa 
cysteine-rich outer membrane protein (omp3) (Hatch et al., 1984), and several polymorphic membrane 
proteins (Pmp). Inside the envelope, C. pneumoniae has a condensed nucleoid structure, which can be 
visualized at the beginning of an infection (Chi et al., 1987). This structure is a combination of DNA and 
histone-like proteins, which are not normally found in prokaryotes. The Chlamydia genome contains two 
genes for histone-like proteins, Hc1 and Hc2 (Kalman et al., 1999). Hc2 has probably some role in 
 15
controlling stage-specific gene expression, whereas Hc1 is responsible for the silencing of gene 
expression at the end of the Chlamydia development cycle (Pedersen et al., 1994).  
 
5.1.4 Genome 
The size of the C. pneumoniae genome is only about 1.2 million bases, and it contains 1072 likely 
protein-coding genes (Kalman et al., 1999). This is a rather small genome even on the prokaryotic scale. 
The obvious reason for the small genome is the intracellular life style of Chlamydia, which enables it to 
acquire nutrients and structural components easily from the host cell. This reduces the amount of 
enzymes needed to synthesize various essential molecules. The lack of suitable methods for genetic 
manipulation of the Chlamydia genome has made it very difficult to study the functions of individual 
genes, but sequence comparisons with genes with known functions in other bacteria have proposed some 
role for 60% of the C. pneumoniae genes (Kalman et al., 1999). According to these annotations, C. 
pneumoniae should have the tools to carry out independently some of the essential functions required for 
survival, but most of the essential pathways are incomplete and need certain molecules from the host 
cell. Chlamydia gene expression, which must be regulated accurately due to the very different needs and 
circumstances at the different stages of the development cycle, is controlled by the chlamydial sigma 
factors (Mathews and Timms, 2000). 
 
5.1.5 Interaction with the host cell 
C. pneumoniae is capable of multiplying in several different cell types (Kaukoranta-Tolvanen et al., 
1994). Inside the host cell, C. pneumoniae takes an active role and manipulates the host cell gene 
expression. This is accomplished partly via inc proteins (Rockey et al., 1995), which are located on the 
cytoplasmic side of the inclusion membrane. Although the details of this interaction are unknown, it 
probably involves host cell kinases (Rockey et al., 1997), which are responsible for the regulation of 
most host cell pathways. Another way to interact with the host cell is provided by chlamydial proteins, 
which are secreted into the host cell cytoplasm (Zhong et al., 2001) (Shaw et al., 2002) (Lugert et al., 
2004) (Vandahl et al., 2005). The functions of these secreted proteins are mostly unknown, but at least 
some of them impair host cell defense mechanisms and possess proteolytic activity (Zhong et al., 2001).  
 
 
Microarray experiments with C. pneumoniae infected cells have yielded a lot of new information about 
the bacteria - host cell interaction. Coombes and Mahony (2001) studied the changes in 268 human 
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genes at various time points after C. pneumoniae infection (strain VR-1310) in a human microvascular 
endothelial cell line (HMCE-1) and found 20 genes with changed expression. This small number of 
affected genes encouraged them to conclude that the endothelial response to C. pneumoniae infection is 
quite limited at the messenger RNA (mRNA) level. Virok et al. (2003) did their microarray work with 
2032 genes using a monocytic cell line (U937) and the C. pneumoniae strain AR-39 and found 128 
genes that were affected by the infection. Most of the up-regulated genes they discovered were linked to 
pro-inflammatory functions, whereas most of the down-regulated genes were related to DNA and RNA 
metabolism or cell cycle regulation. Hess et al. (2003) used 12 000 genes in their microarray 
experiments and compared the changes in host cell (human cervical ephitelial HeLa cell) gene 
expression after C. pneumoniae infection to the changes following C. trachomatis and Salmonella 
typhimurium infections. They concluded that both chlamydia species has a highly similar, substantial, 
and actively controlled effect on the host cell gene expression. Mannonen et al. (2007) focused on the 
gene expression changes specific to persistent C. pneumoniae infection, induced by interferon gamma, 
and were able to establish several previously unknown modifications in host-cell gene expression. They 
used the HL cell line and found 29 genes (out of a total of ~4000) whose expression was changed 
significantly and over twofold due to the persistent infection. Shi and Tokunaga (2004) studied the effect 
of acute C. pneumoniae infection on umbilical vein endothelial cells, using a cDNA array with 588 
human cardiovascular genes, and found support for the assumption that C. pneumoniae participates in 
atherosclerotic development in vivo. As a conclusion of these articles, it can be said that, although the 
authors found some common genes, the overall patterns of up- and down-regulated genes were very 
different. This is probably due to two factors: the biological aspect, meaning the different host cells, 
different C. pneumoniae strains, different amounts of C. pneumoniae in the infection protocols, etc., and 
the technical aspect, meaning the different microchips, different RNA labeling procedures, different data 
normalization, etc.       
       
5.1.6 Clinical manifestations 
 
C. pneumoniae spreads from person to person via respiratory droplets and can infect lung and 
respiratory cells. Although C. pneumoniae is a common bacterium, C. pneumoniae infections are 
diagnosed rarely, since most of them are asymptomatic or mild. In Finland, 10 – 20% of pneumonia 
cases (between epidemics) are caused by C. pneumoniae (Jokinen et al., 2001). Acute C. pneumoniae 
infection can cause mild upper respiratory track infections, pharyngitis or sinusitis, and also lower 
respiratory track infections, such as bronchitis and pneumonia (Grayston et al., 1990). The above-
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mentioned disease are rarely life-threatening, but much more serious diseases have recently been 
associated with chronic C. pneumonia infection. This kind of infection can develop when the Chlamydia 
development cycle cannot be completed normally, and the bacterium converts to an aberrant, but viable 
persistent form (Fig. 1). The persistent form can be induced in different cell types by, for example, 
interferon-gamma (Beatty et al., 1993), iron restriction (Raulston, 1997), or penicillin (Matsumoto and 
Manire, 1970), but it can also develop “naturally” without any additional substances in human 
monocytes (Koehler et al., 1997). This natural way of persistence might be of extreme importance, since 
human immune cells (monocytes and macrophages) are capable of harboring the persistent form and 
spreading it around the body, at least in animal models (Moazed et al., 1998). The most common and 
dangerous disease linked to chronic C. pneumonia infection is atherosclerosis. Saikku and colleagues 
discovered the connection between these two conditions in 1988 (Saikku et al., 1988). After this, several 
studies have supported this finding (Epstein et al., 1999), (Leinonen and Saikku, 2002), (Libby et al., 
1997), but the final causative evidence is still to come. Other severe diseases connected with chronic C. 
pneumoniae infection are asthma, chronic obstructive pulmonary disease (Hahn, 1999), and lung cancer 
(Kuo et al., 1995), but as in the case of atherosclerosis, the role of C. pneumoniae in the pathogenesis of 
these diseases is still unclear. 
 
5.1.7  Treatment 
C. pneumoniae is susceptible to some antibiotics, such as erythromycin, tetracycline, and doxycycline 
(Kuo and Grayston, 1988), which are the most widely used treatments for acute infections, but some 
fluoroquinolones (Miyashita et al., 1997) and ketolides (Roblin and Hammerschlag, 1998)  have also 
demonstrated in vitro activity. Symptoms of C. pneumonia infection can recur, or infection can turn 
persistent despite treatment with these antibiotics (Hammerschlag et al., 1992b), and as mentioned 
earlier, it is also possible to induce a chronic infection with certain antibiotics (Matsumoto and Manire, 
1970). Therefore, more intensive long-term treatments are recommended (Kuo et al., 1995), but there 
are no general guidelines for problematic situations, such as persistence or relapse of symptoms. In 
addition, more recent evidence suggests that C. pneumoniae infection in circulating human monocytes is 
refractory to antibiotic treatment (Gieffers et al., 2001) (Baltch et al., 2004). When these pieces of 
evidence are combined with the fact that there is no effective treatment for persistent C. pneumoniae 
infection, it is obvious that more research and new compounds are needed in this area.   
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5.1.8 Diagnostics 
Acute C. pneumoniae infections are usually diagnosed using serology. A positive result requires a 
fourfold increase in IgM or IgG paired sera taken several weeks apart or single IgM > 16 or single IgG > 
512 (Grayston et al., 1990). Antibodies are generally measured with the microimmunofluorescence 
(MIF) test develop by Wang and Grayston (1970). This test uses EBs as antigens and is capable of 
measuring separately IgG and IgM antibody levels. This is important, since it helps to differentiate 
between past and recent infections as well as between primary and re-infections (Kuo et al., 1995). 
Another way to study C. pneumoniae antibody levels is the complement fixation test, but this method 
has problems with specificity and sensitivity. On the positive side, it measures antibodies against 
chlamydial LPS, which are produced much earlier than IgA, IgG, or IgM antibodies, and it is also much 
easier to use than the MIF test. 
  
Culturing has been most widely used method in C. trachomatis diagnostics, but these days it is replaced 
by different commercial nucleic acid amplification tests. Culturing is not suitable for C. pneumoniae 
diagnostics due to problems with isolation, successful growing, and sensitivity. Also, this technique 
requires good transportation and refrigeration facilities, in order to keep the bacteria infective.   
 
Polymerase chain reaction (PCR) is capable of detecting small numbers of C. pneumoniae specific 
nucleic acids from a variety of samples. It can also be modified and used to determine whether C. 
pneumoniae is active or inactive. The PCR technique has superior sensitivity compared to the other 
methods, but it provides too many false negative and positive findings (Apfalter et al., 2001). If these 
problems can be overcome, and standardized robust protocols can be developed, this method has the 
potential to take chlamydial diagnostics to the next level.        
 
Although acute C. pneumoniae can sometimes be difficult to diagnose, there are much greater problems 
in the diagnostics of chronic infection, which is extremely difficult to distinguish from repeated 
infections by means of the current diagnostic methods. This is related to the fact that chronic C. 
pneumoniae infections can hide deep inside tissue where it is difficult to get decent samples. Usually, 
the diagnosis of chronic infection is based on IgG and especially IgA antibodies, but there are no clinical 
criteria for the diagnosis of chronic infection.  
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5.2 Drug discovery 
Drug discovery is a multi-million dollar business. It has been estimated that pharmaceutical companies 
spend an average of 609 million euros to on the development of a new drug, of which sum about 40% is 
used in the pre-clinical phase (DiMasi et al., 2003).  
Bioactivity screening has been the central part of the drug development process for a long time. In this 
process, the activities of compounds are evaluated against a potential target molecule, disease model, or 
micro-organism. In the pharmaceutical industry, this screening is currently done in a high-throughput 
manner (DiMasi et al., 2003). Compared to traditional screening systems, HTS is simple, rapid, 
effective, and economical. Automated HTS robots and workstations can screen over 100 000 compounds 
in a day (Liu et al., 2004).  
 
5.2.1 Drug screening 
Advances in sequencing technology increased the number of potential drug targets dramatically in the 
early 1990s (Koehn and Carter, 2005). At the same time, the development of combinatorial chemistry 
techniques enabled the creation of enormous synthetic libraries, which could easily be screened in the 
HTS environment. Although natural products are excellent sources of drug candidates due to their high 
chemical diversity and biochemical specificity, the more difficult and time-consuming nature of natural 
compound libraries prompted pharmaceutical industry to use synthetic libraries (Newman et al., 2003). 
This trend cost substantial amounts of money to pharmaceutical companies, but did not pay off in the 
expected way (Schmid and Smith, 2004), and the number of NCEs was declining at the beginning of the 
millennium (Graul and Prous, 2006). In retrospect, the biggest reason for this failure was probably the 
lack of structural diversity among synthetic compounds (Payne et al., 2007). This view is also supported 
by several comparative studies on the structural diversity of synthetic and natural libraries (Feher and 
Schmidt, 2003), (Lee and Schneider, 2001), (Stahura et al., 2000), which have agreed on the greater 
diversity of natural libraries.  
 
 
Currently, pharmaceutical industry is in a situation where novel compounds are urgently needed. This is 
a problem, since it is not possible to create adequate diversity with the current synthetic methods, and 
since the natural products that possess this diversity are often unsuited to HTS (Feher and Schmidt, 
2003). Pharmaceutical industry is addressing this problem in two ways: firstly, by making natural 
product libraries more suitable for HTS by, for example, using fractionated natural products libraries, 
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and secondly, by developing methods of combinatorial synthesis to enhance the structural complexity of 
synthesized compounds (Koehn and Carter, 2005).      
 
5.2.1.1 Natural products 
A natural product is a compound or substance produced by a living organism. Two groups of organisms, 
namely plants and microbes, have been the source and the innovation of most pharmaceutically relevant 
natural compounds. These biologically active compounds are usually secondary metabolites that are 
produced after external stimuli, such as infection (Strohl, 2000). Due to their specialized biochemical 
capabilities, plants and microbes can synthesize a vast array of structurally diverse chemical compounds, 
which can be used as protection against environmental factors. Between 1981 and 2002, 33% of new 
NCEs were purely synthetic. Of the remaining ones, 3% were vaccines, 5% were pure natural products, 
and the rest were somehow related to nature, e.g. nature-based pharmacophores, or derivatives of natural 
products (Newman et al., 2003).  
 
Microbes are the source of some of the best-selling drugs today, and they still continue to be the most 
promising source of new antibiotics (Pelaez, 2006). The revolutionary discovery of penicillin by the 
Scottish scientist Sir Alexander Fleming in 1928 was soon followed by the discovery of other antibiotics 
of bacterial or fungal origin, whose chemical scaffolds are still used in the development of new 
antibiotics. The major problem with these “old” antibiotics and their derivatives is the fast evolving 
resistance (Singh and Barrett, 2006). Although pharmaceutical industry is aware of this threat, there are 
economic, regulatory, and scientific reasons to explain the reluctance to develop new antibiotics 
(Nathan, 2004). As a consequence, only three new antibiotics classes have entered the marketd in the 
last 25 years (Butler and Buss, 2006).     
 
 
Biologically active compounds have made several plants useful for man since ancient times as spices or 
medicines, and they still continue to be an inspiration and important source of new medicines for 
pharmaceutical industry. Plant-derived compounds are known to have a variety of beneficial effect on 
the human body. There are well-documented cases of the ability of plant compounds to control cell 
division and proliferation, platelet aggregation, detoxification, and inflammatory as well as immune 
responses (Manthey, 2000) (Middleton and Kandaswami, 1992), and there are also several plant-derived 
anti-cancer compounds in clinical use (Cragg and Newman, 2005). Despite the recent reduction in 
natural product operations in big pharmaceutical companies, medical plant discovery continues to 
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produce new lead molecules against various diseases such as Alzheimer's, malaria, and HIV/AIDS, but 
the full potential of plant-derived compounds can only be exploited if the above-mentioned challenges 
concerning HTS bioassays can be resolved (Balunas and Kinghorn, 2005).   
 
5.2.1.2 Synthetic libraries and combinatorial chemistry 
Synthetic libraries play an important role in the drug development process, but the basic problem with 
these libraries has traditionally been their lack of diversity (Payne et al., 2007). Combinatorial chemistry 
has provided a partial solution of this problem. Combinatorial technology means synthetic technologies 
that are able to generate compound libraries rather than single compounds. Thousands of combinatorial 
libraries have been produced since the first small-molecule combinatorial library was introduced in the 
early 1990s (Gershell and Atkins, 2003). Originally, this technique was developed for the synthesis of 
peptide and oligonucleotide libraries (Furka et al., 1991), but it was later modified to cover small 
molecules. The basic idea of combinatorial chemistry is to simultaneously synthesize large amounts of 
different compounds in a short period of time. Combinatorial techniques enable the combination of a 
number of chemical building blocks in different ways. In pharmaceutical industry, combinatorial 
chemistry is mainly used to create “focused” or “prospecting” libraries (Spaller et al., 1997). Focused 
libraries consist of different modifications of a molecule with known activity and are used to find 
alternatives to this structure, whereas prospecting libraries consist of novel structures.  
 
5.2.1.3 Virtual screening 
 
HTS utilizes large compound libraries and sophisticated automated systems, which are often 
inaccessible to scientists outside the pharmaceutical industry. Virtual screening is a computer-assisted 
way to create smaller, focused libraries, against a known target. Such libraries can be created by using a 
target protein or the structure of a known ligand as a starting point. The former option requires a 3D 
crystal structure of the target protein. This 3D structure can also be a “comparative model”, which is 
created using the known 3D structures of closely related proteins. Small molecular structures are docked 
on the computer screen to the preferred place on the protein, in order to find the best binders. Ligand-
based libraries use known active compounds as templates and try to create even more active compounds 
or find active compounds with better physicochemical properties. Since these focused libraries are rather 
small, they can be tested in a suitable bioassay without automation. They can also be designed for drug 
screening purposes by choosing only compounds with drug-like properties (Lipinski et al., 1997). The 
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limitations of this technology are related to the accuracy of the different variables that specify 
compounds and targets, and when virtual compounds are used, to the number of compounds that can be 
actually synthesized based on their virtual model (Gershell and Atkins, 2003).    
 
5.2.2 Genomics 
Genomics means the study of an organism's entire genome. The interest for such research began to 
emerge more than 20 years ago, and it exploded after the first genomes of unicellular (Fleischmann et 
al., 1995) and, later, multicellular (C. elegans Sequencing Consortium, 1998) organisms had been 
sequenced. The major breakthrough in this area took place in 2001, when the first draft of the human 
genome was released (Venter et al., 2001). Two years later, 100 complete genome sequences had been 
submitted to databases (Janssen et al., 2003), and the recent development in sequencing technology 
makes it difficult to estimate the current number of completed genomes.       
 
5.2.2.1 Microarrays 
Genome-wide studies are conducted with microarrays (Schena et al., 1995). Usually, these arrays are 
used to probe the differences in gene expression after exposure to some substance, bacterium, or 
condition. They consist of either DNA fragments from the investigated organism or oligonucleotides, 
which are short sequences of synthetic nucleotides (DNA or RNA) corresponding to the gene sequence 
of the investigated organism. In both cases, the idea is to capture labeled complementary DNA 
molecules, which are synthesized from the mRNAs of individual genes, to a single spot on the array. 
When complementary DNA molecules from different conditions are labeled with different colors, the 
proportion of color on a spot reflects the change in the expression of that gene between the studied 
conditions. A single microarray may contain tens of thousands of spots. 
 
 
Microarrays can be used at several stages in the drug development process (Gerhold et al., 2002). First, 
microchips are used at the drug discovery stage in order to find genes or pathways that are suitable drug 
targets. Usually, cell lines are infected or altered to resemble a disease, and changes in the gene 
expression profile are monitored. The goal is to find genes or gene pathways that are crucial for the 
disease process, to use these genes or their products as targets, and to screen or design molecules against 
them in order to stop the progression of the disease. The target validation stage confirms that the 
selected target is, in fact, crucial for the disease, and microchips are used to monitor the changes that 
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take place when the gene that encodes this target is “turned off”. This data is used to find the targets that 
affect only the same genes or gene pathways as the disease and, because of this, hopefully do not cause 
any side effects (Gerhold et al., 2002). In the lead molecule optimization process, microarrays are used 
in the characterization, optimization, and finally, selection of the best lead molecule by studying the 
expression profiles caused by the lead candidate compounds. This selection process also involves studies 
on metabolism and toxicology. In these studies, the expression profiles of potential drug compounds are 
compared to the profiles of well-known compounds with desirable/undesirable metabolism and 
toxicology profiles.    
  
The utilization of microarrays in drug development is not limited to the pre-clinical phase. Disease 
versus control studies can also be utilized in the clinical research (Weeraratna et al., 2004), and there are 
clinical screening programs where microarrays are used to predict the best possible treatment (Schubert, 
2003). In addition, microarrays are in themselves valuable diagnostic, prognostic, and predictive tools 
(Pusztai et al., 2003), but their full potential in clinical trials can only be utilized after the problems 
related to biological, methodological, and statistical issues have been resolved (Olson, 2004).   
 
5.2.3 Proteomics 
The word “proteome” refers to all the proteins produced by an organism, and “proteomics”, first 
described in 1969 (Macko and Stegemann, 1969), is the study of their expression, structure, and function 
(Persidis, 1998). Proteomics is the next logical step after genomics, since most of the cell functions take 
place at the protein level. The changes at the protein level are more relevant for the cell, but there are no 
methods able to quantify and identify proteins on the global scale, although there has been promising 
development in the proteomics methodology in the recent years (Arthur, 2003). The active interest in 
proteomics is due to the fact that changes at the transcription level do not necessarily show up at the 
protein level. There are several reasons for this, including the rapid degradation or inefficient translation 
of messenger RNA, and the major advance of proteomics, compared to microarrays, is that it can also 
detect protein isoforms resulting from post-translational modifications, proteolytic processing, or 
alternative mRNA splicing caused by the given condition.    
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5.2.3.1 Two-dimensional polyacrylamide gel electrophoresis 
The basic idea of proteomics is first to separate and then to identify individual proteins. Today, the most 
widely used proteomics tool is two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) coupled 
with mass spectrophotometry (MS). In this system, proteins are separated as spots in a gel using 2D-
PAGE and identified with MS. Separation on the first dimension (horizontal) is done using a tube gel or 
an immobilized pH gradient strip, and it is based on the isoelectric point of the protein (Klose and 
Kobalz, 1995). Separation on the second dimension (vertical) is based on the mass of the protein, and it 
is done using electrophoresis. After these separations, the proteins are visualized with a stain. Individual 
protein spots are then cut off from the gel and identified in MS. There are problems related to solubility 
and the separation of structurally similar proteins, but this method can give valuable information about 
the relevant changes inside the cell.   
 
Pharmaceutical industry has taken a cautious approach towards proteomics, mainly because of the recent 
large investments in the genomic and HTS area (Hanash, 2003). Currently, proteomics is used mostly in 
expression proteomics studies in drug / biomarker discovery as well as in toxicoproteomics. Expression 
proteomics tries to identify and characterize proteins that are expressed differently in cell lines, tissues, 
or organisms under given condition. The aim of these studies is to find proteins that can be used as drug 
targets (Van Eyk, 2001) or diagnostic biomarkers (Petricoin et al., 2002). In toxicity testing, proteomics 
is used to identify altered proteins or protein pathways after drug treatment (Wetmore and Merrick, 
2004).     
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6 AIMS OF THE STUDY 
 
The overall aim of this thesis was to find compounds and specific target molecules that could be used in 
the treatment of C. pneumoniae infections. The screening of anti-chlamydial compounds was done using 
focused libraries t suitable for an academic environment. Specific target molecules were searched using 
genomics and proteomics.  
 
The specific aims of the study were to: 
 
1. Search for potent compounds against C. pneumoniae infection in vitro  
 
2. Develop a new high-throughput screening method and screen natural and synthetic compounds 
for molecules that inhibit C. pneumoniae growth. 
 
3. Study the effects of C. pneumoniae infection on the host cell’s gene and protein expression at 
different stages of the infection. 
 
4. Identify new potential drug targets for the treatment of C. pneumoniae infection using 
proteomics and genomics data. 
 
5. Validate the significance of the discovered potential drug target genes by silencing them with 
specific siRNA molecules and measuring the effect of silencing on the number of C. 
pneumoniae particles. 
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7 EXPERIMENTAL 
 
7.1 Materials 
7.1.1 Cell line and chlamydia strains (I -V) 
The human epithelial cell line (HL) (Cles and Stamm, 1990) used in this study was cultivated in RPMI 
1640 medium (BioWhittaker Europe, Verviers, Belgium) supplemented with 7.5% of heat-inactivated 
fetal bovine serum of South American origin (BioWhittaker Europe), 2mM L-glutamine, and 20 μg/ml 
streptomycin. The cells were kept at 37°C and 95% humidity in an atmosphere containing 5% CO2. 
 
The chlamydial strains used in this study (Table 1) were purified from infected cells by Urografin 
(Schering Ag, Berlin, Germany) gradient ultracentrifugation. Chlamydial EBs were stored in sucrose–
phosphate–glutamic acid buffer (0.2M sucrose, 3.8mM KH2PO4, 6.7mM Na2HPO4, and 5mM L-
glutamic acid, pH 7.4) at -70°C. 
Table 1. Chlamydial strains 
Bacterial strains Description Article Source 
C. pneumoniae K7 C. pneumoniae isolate Kajaani 7 I, II, III 
(Ekman et al., 
1993a)  
C. pneumoniae CWL-027 C. pneumoniae isolate IV, V ATCC number VR-1310 
 
7.1.2 Pure compounds and synthetic derivatives (I) 
The plant-derived pure compounds and synthetic derivatives used in this study are presented in Table 2. 
All compounds were dissolved in dimethyl sulfoxide (DMSO); the final concentration of DMSO during 
the experiments was 0.5%, and it did not affect the host cells or the infection. 
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Table 2. Plant-derived pure compounds and synthetic derivatives.  
 
Compound Description Article Source 
Acacetin  Flavones I Carl Roth GmbH 
Apigenin  Flavones I Fluka 
Daidzein  Isoflavones I Extrasynthese 
Daidzin  Isoflavones I Extrasynthese 
Flavone  Flavones I Carl Roth GmbH 
Genistein Isoflavones I Extrasynthese 
Genistin  Isoflavones I Extrasynthese 
Isorhamnetin  Flavonols I Extrasynthese 
Kaempherol  Flavonols I Extrasynthese 
Luteolin  Flavones I Extrasynthese 
Luteolin- 7 –glucoside  Flavones I Extrasynthese 
Luteolin-3',7-glucoside  Flavones I Extrasynthese 
Morin  Flavonols I Carl Roth GmbH 
Myricetin  Flavonols I Extrasynthese 
Naringenin  Flavanones I Sigma 
Naringin  Flavanones I Extrasynthese 
Procyanidin B l  Catechins I Extrasynthese 
Procyanidin B2 Catechins I Extrasynthese 
Quercetin  Flavonols I Merck 
Quercitrin  Flavonols I Carl Roth GmbH 
Rhamnetin  Flavonols I Extrasynthese 
Rutin  Flavonols I Merck 
Vitexin  Flavones I Extrasynthese 
Vitexin-2"-O-rhamnoside Flavones I Extrasynthese 
Benzoic acid  Phenolic acids I Merck 
Caffeic acid  Phenolic acids I Sigma 
Dodecyl gallate  Gallates I Fluka 
Ferulic acid  Phenolic acids I Extrasynthese 
Gallic acid  Phenolic acids I Sigma 
Methyl gallate  Gallates I Fluka 
Octyl gallate  Gallates I Extrasynthese 
Propyl gallate  Gallates I Sigma 
Syringic acid  Phenolic acids I Sigma 
Resveratrole  Stilbene I Extrasynthese 
(+)-Catechin  Catechins I Sigma 
Coumarin  Natural coumarins I Sigma 
(-)-Epicatechin  Catechins I Sigma 
(-)-Epicatechin gallate  Gallates I Extrasynthese 
(-)-Epigallocatechin  Catechins I Extrasynthese 
Methoxy psoralen  Natural coumarins I Fluka 
Scopoletin  Natural coumarins I Sigma 
Umbelliferone  Natural coumarins I Sigma 
Xanthotoxin  Natural coumarins I Extrasynthese 
2 '-methoxy-a-naphtoflavone Synthetic flavonoids I ICC chemical corporation 
3-(2-benzoxazoyl)umbelliferone  Synthetic coumarins I Fluka 
3 -(a-acetonylbenzyl)-4-hydroxycoumari Synthetic coumarins I Sigma 
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3-benzoylbenzo(F)coumarin  Synthetic coumarins I Acros 
4-methyl-3-phenylcoumarin  Synthetic coumarins I Sigma 
6-methylcoumarin  Synthetic coumarins I Extrasynthese 
6,2 , -dimethoxyflavone  Synthetic flavonoids I Sigma 
6,8-dibromocoumarin-3-carboxylic 
acid 
Synthetic coumarins I Avocado 
7-diethylamino-3-thenoylcoumarin  Synthetic coumarins I Acros 
Alpha-naphtoflavone  Synthetic flavonoids I Acros 
Coumarin 30  Synthetic coumarins I MP Biomedicals 
Coumarin 102  Synthetic coumarins I Acros 
Coumarin 106  Synthetic coumarins I Acros 
Rotenone  Synthetic flavonoids I Acros 
 
7.1.3 Antimicrobial agents (II) 
To determine the minimal inhibitory concentration (MIC) of C. pneumoniae, fresh solutions of 
antimicrobial agents (Table 3) were prepared for each experiment. All agents were dissolved in DMSO; 
the final concentration of DMSO during the experiments was 0.2%, and it did not affect the host cells or 
the infection. 
Table 3. Antimicrobial agents used in this study. 
Antimicrobial agents Description Article Source 
Erythromycin Commercial antibiotic II Sigma 
Streptomycin Commercial antibiotic II Sigma 
Rifampicin Commercial antibiotic II Sigma 
Doxycycline Commercial antibiotic II ICN Biomedicals 
Ofloxacin Commercial antibiotic II ICN Biomedicals 
Minocycline Commercial antibiotic II ICN Biomedicals 
Ciprofloxacin Commercial antibiotic II ICN Biomedicals 
 
7.1.4 Synthetic compounds (III) 
 
The X-ray crystal structure of a potential C. pneumoniae target protein homologue (Bacillus subtilis 
RNA methyltransferase; coded by the ermC gene) was used in the virtual screening of approx. 300 000 
commercial compounds in order to create a targeted library against the selected C. pneumoniae target 
protein (dimethyladenosine transferase; coded by the ksgA gene). After the virtual screening process, the 
2000 best binding molecules, as ranked by the FlexX program, were analyzed visually, and the 33 most 
promising molecules (Table 4.) with good docking orientations were ordered from Specs (Delft, 
Netherlands) and Maybridge (Cornwall, England). 
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Table 4. The compounds S1 – S12 were ordered from Specs and MB1 – MB21 from Maybridge. 
 
7.1.5 Microarrays and scanner (IV) 
RNA extracted from infected and uninfected cells was labeled with the RNA labeling kit (Agilent 
Fluorescent Direct Labeling Kit, Agilent, USA) and hybridized to the Agilent Technologies (Santa 
Clara, CA   95051, United States) human 1A oligo microarrays (V2). The microarrays were scanned 
with a GenePix 4200 autoloader scanner (Axon instruments). 
 
Abbreviation International Union of Pure and Applied Chemistry (IUPAC) names 
S1 2-{4-amino-6-[(4-chlorophenyl)amino]-1,3,5-triazin-2-yl}-4-chlorophenol 
N-1,3-benzodioxol-5-yl-2-[(5-methyl-1H-benzimidazol-2-yl)thio]acetamide 
S2 2-(1H-benzimidazol-2-ylthio)-N-(3-hydroxyphenyl)acetamide 
S3 N-(3-fluorophenyl)-2-(3H-imidazo[4,5-b]pyridin-2-ylthio)acetamide 
S4 2-(3H-imidazo[4,5-b]pyridin-2-ylthio)-N-phenylacetamide 
S5 N-1,3-benzodioxol-5-yl-2-(3H-imidazo[4,5-b]pyridin-2-ylthio)acetamide 
S6 N-1,3-benzodioxol-5-yl-2-(3H-imidazo[4,5-b]pyridin-2-ylthio)acetamide 
S7 2-[(1H-benzimidazol-2-ylmethyl)thio]-3H-imidazo[4,5-b]pyridine 
S8 N-[3-(acetylamino)phenyl]-4-methoxybenzamide 
S9 3-[(2,5-dichlorophenoxy)methyl]-N-2,3-dihydro-1,4-benzodioxin-6-ylbenzamide 
S10 N-(2,4-difluorophenyl)-2-(3H-imidazo[4,5-b]pyridin-2-ylthio)acetamide 
S11 N-(4-fluorophenyl)-2-(3H-imidazo[4,5-b]pyridin-2-ylthio)acetamide 
S12 N-1,3-benzodioxol-5-yl-2-[(5-methoxy-1H-benzimidazol-2-yl)thio]acetamide 
MB1 N-(1,3-benzodioxol-5-ylmethyl)-6-phenylthieno[3,2-d]pyrimidin-4-amine 
MB2 N-[3-(1H-benzimidazol-2-yl)phenyl]-4-fluorobenzamide 
MB3 N-[3-(1H-benzimidazol-2-yl)phenyl]-4-methylbenzamide 
MB4 N-[3-(1H-benzimidazol-2-yl)phenyl]thiophene-2-carboxamide 
MB5 N-[3-(1H-benzimidazol-2-yl)phenyl]benzamide 
MB6 N-[3-(1H-benzimidazol-2-yl)phenyl]-4-methoxybenzamide 
MB7 N-2,3-dihydro-1,4-benzodioxin-6-ylbenzamide 
MB8 N-2,3-dihydro-1,4-benzodioxin-6-yl-4-methoxybenzamide 
MB9 N-(4-morpholine-4-aminobenzyl)-3,4-dihydro-2H-1,5-benzodioxepine-7-carboxamide 
MB10 9-{2-[(1,3-benzodioxol-5-ylmethyl)amino]ethyl}-9H-purin-6-amine 
MB11 N-{4-[(pyrimidin-2-ylamino)sulfonyl]phenyl}acetamide 
MB12 N'-[(anilinocarbonyl)oxy]-2,1,3-benzoxadiazole-5-carboximidamide 
MB13 N'-({[(3-chlorophenyl)amino]carbonyl}oxy)-2,1,3-benzoxadiazole-5-carboximidamide 
MB14 2-[(2,1,3-benzoxadiazol-5-yloxy)methyl]-N-(4-chlorophenyl)-1,3-thiazole-4-carboxamide 
MB15 2-[(2,1,3-benzoxadiazol-5-yloxy)methyl]-N-(4-nitrophenyl)-1,3-thiazole-4-carboxamide 
MB16 N2,N4-diphenyl-1,3,5-triazine-2,4,6-triamine 
MB17 N-benzyl-9H-purin-6-amine 
MB18 N-(2-furylmethyl)-9H-purin-6-amine 
MB19 N-(3-nitrophenyl)-1,3,5-triazine-2,4-diamine 
MB20 4-chloro-N-(2-{[(6-nitro-4H-1,3-benzodioxin-8 yl)methyl]thio}phenyl) benzamide 
MB21 N-(2-{[(6-nitro-4H-1,3-benzodioxin-8-yl)methyl]thio}phenyl)thiophene-2-carboxamide 
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7.2 Methods 
7.2.1 Mycoplasma detection (I, IV, V)  
Mycoplasma detection from the HL cell line was done with either the mycoplasma Plus PCR Primer Set 
(Stratagene, California, USA) (IV) or Mycoplasma PCR ELISA (Roche Diagnostics, Mannheim, 
Germany) (I and V) 
 
7.2.2 Infection protocol (I - V) 
In the 6-well plate experiments 3.5 x 106 (IV) or 3 x 106 HL cells/well (V) were allowed to attach to the 
bottom of the wells and the cell monolayers were infected 24 h later with of 7 x 106 (IV) or 6 x 106 (V) 
IFU/well (CWL-029 strain), using 550 x g centrifugation for 60 min at room temperature. After 
infection, the cells were washed once with phosphate-buffered saline, fresh culture medium was added 
to the wells, and the plates were placed into a 5% CO2 atmosphere at 37°C for different periods of time. 
This protocol was used when infected cell were utilized in genomics and proteomics experiments. 
 
In the 24-well plate experiments 4.5 x 105 cells/well were allowed to attach to the coverslips at the 
bottom of the wells. Confluent cell monolayers were infected 24 h later with an infection medium 
supplemented with 0.5 μg/ml of cycloheximide, an 80-s ribosome inhibitor, and 10 x 103 (I) or 8 x 104 
(II) IFU/well (K7 strain) using 550 x g centrifugation for 60 min at room temperature. After infection, 
the cells were washed once with phosphate-buffered saline, fresh culture medium containing 
cycloheximide and the tested compound was added to the wells, and the plates were placed into a 5% 
CO2 atmosphere at 37°C for 72 h. This protocol was used when C. pneumoniae inclusions were counted 
after IF staining. 
 
 
In the 96-well plate experiments, 6 x 104 (II and IV) or 5 x 104 (III) cells/well were allowed to attach to 
the clear-bottomed 96-well plates. Confluent cell monolayers were infected 24 h later with an infection 
medium supplemented with 0.5 μg/ml of cycloheximide (II and III), an 80-s ribosome inhibitor, and 1.4 
x 104 (II), 8 x 104 (III) or 1.2 x 105 (IV) IFU/well (K7 in II and III and CWL-029 in IV) using 550 x g 
centrifugation for 60 min at room temperature. After infection, the cells were washed once with 
phosphate-buffered saline, fresh culture medium containing cycloheximide and the tested compound (II 
and III) or siRNA molecule (IV) was added to the wells, and the plates were placed into a 5% CO2 
atmosphere at 37°C for 72 h. This protocol was used in the TR-FIA measurements. 
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7.2.3 Cytotoxicity testing (I, III, IV) 
The Lactate dehydrogenase (LDH) kit (CytoTox, Promega, USA) (I and III) and the Adenosine 
triphosphate (ATP) kit (ATPlite 1step, PerkinElmer Life and Analytical Sciences, USA) (IV) were used 
according to the manufacturers’ instruction in order to detect the possible cytotoxicity of the tested 
compounds (I and III) or siRNA molecules (IV). 
 
7.2.4 Nucleic acid isolation and q-PCR (II, IV) 
DNA was extracted from infected and uninfected cells using a DNA mini kit (Qiagen), according to the 
manufacturer’s instructions (II).  
 
Q-PCR with SYBR Green dye was used for the relative quantification of C. pneumoniae DNA in the 
samples, using a LightCycler instrument (Roche Biochemicals) and the FastStart DNA Master SYBR 
Green I kit (Roche Biochemicals), VD-4 primers, and the cycling conditions described by Tondella et al. 
(Tondella et al., 2002) (II). 
 
Total RNA was extracted from infected and uninfected cells with the RNeasy kit (Qiagen, Valencia, CA, 
USA) according to the manufacturer’s instructions (IV). 
 
The expression of the selected genes was confirmed with q-PCR. 2 μg of RNA was reverse-transcribed 
using the TagMan Reverse Transcription Reagents, Abgene  - Absolute SYBR Green Rox Mix and ABI 
Prism 7000 Sequence Detection System for q-PCR (IV). The primers that were used in q-PCR are 
shown in Table 1 in IV. 
 
7.2.5 C. pneumoniae detection (I – IV) 
 
The immunofluorescence staining of C. pneumoniae inclusions was done 72 h p.i. The culture medium 
was removed from the wells, and the coverslips were washed once with PBS and fixed in methanol for 
10 min. The coverslips were allowed to dry, and the chlamydial inclusions were stained directly with 
fluorescein isothiocyanate (FITC)-conjugated chlamydial genus-specific antibody (PathFinder1 
Chlamydia Culture Confirmation System, Bio-Rad S.A., WA, USA). The stained inclusions were 
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examined under a fluorescence microscope (Nikon ECLIPSE TE300 inverted microscope with TE-FM 
epi-fluorescence attachment, Tokyo, Japan) (I and II). 
 
In the TR-FIA protocol, infected HL cells were fixed in 96-well plates and labeled with a genus-specific 
murine monoclonal antibody (Argene SA, Varilhes, France) containing an europium label 
(PerkinElmer/Wallac Oy, Turku, Finland). After 30-min labeling at 37 °C, the plates were washed six 
times with a Biohit BW50 platewasher (Biohit Plc, Finland) using 300 μL of Wallac DELFIA Wash 
Solution (Perkin-Elmer Life and Analytical Sciences/Wallac Oy) each time. An aliquot of 100 μL of 
DELFIA Enhancement Solution (PerkinElmer) was added to each well, and the plates were shaken for 5 
min at low speed on a DELFIA Plateshake (PerkinElmer). Signals associated with the Chlamydia 
antibody were measured from the wells with a Wallac Victor2 multilabel counter (PerkinElmer) (II, III 
and IV). 
  
7.2.6 Virtual screening (III) 
The peptide chain from the X-ray crystal structure 1QAO was used as the target protein. The structure 
was pre-processed in the Sybyl software, version 6.5 (Tripos Inc., St. Louis, USA). The atom types of 
carboxylic acid oxygens were set to O.co2 and those of basic nitrogens to N.4. Hydrogens were added to 
the model, and their orientation was optimized using Tripos force field energy minimization, while all 
non-hydrogen atoms were not allowed to move (III). 
 
The ligand position in 1QAO was used to define the active site cavity. Default FlexX (Sybyl 6.5) 
parameters were used. The 2000 top ranking molecules were further inspected visually to exclude any 
structures with improbable docking orientation, and 33 molecules with good docking orientations were 
chosen for biological testing (III). 
 
7.2.7 Gene silencing (IV) 
 
SiRNAs molecules were ordered from Qiagen (Valencia, CA, USA) (IV). Gene silencing was executed 
using Qiagens HiPerFect Transfection Reagent in line with the HiPerFect Transfection Reagent 
Handbook instructions. Two siRNAs were tested for each gene. The results were validated in the ABI 
Prism 7000 Sequence Detection System (Applied Biosystem, USA) using “Hs_GAPD_5 HP Validated 
siRNA” as a positive control and “control (non-silence) siRNA” as a negative control. 
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8 RESULTS AND DISCUSSION 
 
The work for this thesis is part of a larger ongoing research project (Fig. 3), which aims to develop new 
specific drug molecules and diagnostic tests for C. pneumoniae infection.  
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Figure 3. A schematic presentation of the entire research project. The grey boxes are included in this 
thesis. 
 
8.1    Screening of active compounds (I, II, III) 
 
The search for anti-chlamydial compounds was started by screening a group of natural and naturally 
derived pure compounds, which were already known to have antimicrobial properties (I). This screening 
was done by using a traditional staining and inclusion counting method, which is laborious and time-
consuming. These reasons led to the development of a new screening assay, which is more automated 
and suitable for high-throughput screening (II). This new assay was used to screen a small targeted 
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library, built with the help of a structural homolog of the selected target, in order to find anti-chlamydial 
activity among the synthetic compounds (III).  
 
8.1.1 Natural products (I) 
A group of natural and natural-based products (57 in total) were screened against C. pneumoniae, and 
the anti-chlamydial activity of these compounds was determined by counting inclusions after 
immunofluorescence staining (Table 5). The in vitro minimum inhibitory concentration (MIC) was also 
determined for some of the most active compounds (Table 1 in I).  
 
Highly active compounds were found from several groups, but gallates were clearly the most active. The 
antibacterial activity of gallates has already been demonstrated in other species, and the length of the 
alkyl group has been found to increase this activity (Kubo et al., 2003). This was also the case in our 
studies (Table 1 in I), since the MIC value for dodecyl gallate was 18 μM (the length of the alkyl group 
was 12 carbons) and that for octyl and methyl gallate 29 μM (the lengths of the alkyl groups were 3 and 
1 carbon, respectively). Inactive compounds were also seen in several groups, but most compounds with 
0% inhibition occurred among synthetic coumarins (Table 5). Natural coumarins, on the other hand, 
were quite active against C. pneumoniae, which is not surprising, since they are already known to have 
antibacterial activity (Ojala et al., 2000). The overall high antichlamydial activity of the phenolic 
compounds included in our study is in good agreement with corresponding studies using different 
phenolics and bacteria (Puupponen-Pimia et al., 2005) (Rauha et al., 2000).  
 
The antimicrobial properties of natural compounds often originate from their ability to interact with 
biological membranes (Maillard, 2002). In order to see whether the compounds in our study have the 
capacity to retain and/or penetrate membranes, HL cells were pre-incubated for 24 h with the 
investigated compound before the actual C. pneumoniae infection.  
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 Table 5. The average inhibition percentages of plant-derived phenolic compounds and some synthetic 
derivatives against C. pneumoniae (50 μM concentration; n=4 or more). The following categories of 
activity were used: Highly active = 85-100% inhibition, compared to DMSO controls; Active = 50-84%; 
Moderately active = 30-49%; Inactive = < 30%. Abbreviations of the compound groups; Catechins (A), 
Gallates (B), Flavanones (C), Flavones (D), Flavonols (E), Isoflavones (F), Natural coumarin (G), 
Phenolic acids (H), Stilbene (I), Synthetic coumarins (J) and Synthetic flavonoids (K). 
 
Highly active Umbelliferone (G) 75 
Compound                         Inhibition % Caffeic acid (H) 78 
Dodecyl gallate (B)  100 Resveratrole (I) 54 
Methyl gallate (B) 100 6-methylcoumarin (J) 71 
Octyl gallate (B) 100 Coumarin 102 (J) 63 
Propyl gallate (B) 100 3-benzoylbenzo(F)coumarin (J) 62 
(-)-Epicatechin gallate (B) 85 Coumarin 30 (J) 50 
Acacetin (D) 100 6,2 , -dimethoxyflavone (K) 73 
Apigenin (D) 100   
Luteolin (D) 100 Moderately active 
Flavone (D)  90 Compound                          Inhibition % 
Morin (E) 100 Procyanidin B l (A)  30 
Myricetin (E) 100 Luteolin-3',7-glucoside (D) 45 
Rhamnetin (E)  100 Rutin (E) 46 
Quercetin (E) 90 Genistin (F) 37 
Methoxy psoralen (G) 100 Benzoic acid (H) 44 
Scopoletin (G) 96 Syringic acid (H) 32 
Xanthotoxin (G) 94   
7-diethylamino-3-thenoylcoumarin (J) 100 Inactive 
Coumarin 106 (J) 100 Compound                         Inhibition %  
2 '-methoxy-a-naphtoflavone (K)  100 Procyanidin B2 (A) 0 
Rotenone (K) 100 Naringenin (C) 16 
Alpha-naphtoflavone (K) 92 Luteolin- 7 –glucoside (D)  23 
  Vitexin-2"-O-rhamnoside (D)  11 
Active Vitexin (D) 3 
Compound                         Inhibition % Kaempherol (E) 15 
(+)-Catechin (A) 76 Daidzin (F) 0 
(-)-Epicatechin (A) 75 Coumarin (G) 28 
(-)-Epigallocatechin (A) 58 Ferulic acid (H) 14 
Naringin (C) 66 Gallic acid (H) 27 
Isorhamnetin (E) 70 3-(2-benzoxazoyl)umbelliferone (J) 28 
Quercitrin (E) 50 3 -(a-acetonylbenzyl)-4-hydroxycoumarin (J) 0 
Genistein (F) 60 4-methyl-3-phenylcoumarin (J)  0 
Daidzein (F) 51 6,8-dibromocoumarin-3-carboxylic acid (J) 0 
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The infection was done according to the infection protocol, and the infected cells were grown in the 
infection medium without the test compound for 72 h (Fig. 4). These results confirmed the previously 
discovered characteristic of these compounds (Tammela et al., 2004), demonstrating that some of them 
have the ability to accumulate inside cells or into cell membranes and reduce the number of C. 
pneumoniae inclusions, even when present only prior to infection.  
 
To analyze if C. pneumoniae could be totally eliminated from the cell cultures, the infectivity of the 
possible C. pneumoniae progenies after exposure to four active compounds was determined (Fig. 4). 
Infected HL cells cultivated with the tested compound were mechanically disrupted after 72 h 
incubation, repassaged on freshly prepared confluent HL cell layers, and incubated for 72 h without the 
compounds.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Effect of pre-treatment and continuous treatment on the formation of chlamydial inclusions 
and the yield of infectious chlamydial particles. Values are average inhibition percentages, compared to 
untreated controls 72 h p.i. 
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The results showed that quercetin, morin, and octyl gallate do not affect the infectivity of newly formed 
EBs, since inclusions could be found after the repassage. Rhamnetin, on the other hand, seemed to have 
an effect on newly formed EBs or it may block the conversion of RBs back to EBs at the end of the 
developmental cycle, since there was 100% inhibition after the repassage, although there were inclusions 
left after the initial 0.5 mM treatment. 
 
The antichlamydial activity of some of the most active compounds of this study, i.e. quercetin, luteolin, 
and octyl gallate, has also been evaluated in vivo (Törmakangas et al., 2005). In these experiments, mice 
were treated for three days before and for ten days after C. pneumoniae inoculation in order to see how 
these compounds modify the course of the infection. Lung tissue analysis, assessment of the 
inflammatory response, and C. pneumoniae antibody levels demonstrated a clear beneficial effect for 
luteolin, no significant effect for octyl gallate, and an unbeneficial effect for quercetin, which was 
speculated to be caused by incorrect dosage and an improper route of administration. The beneficial 
effect of luteolin was due to the decreased number of C. pneumoniae particles in the lung tissue and the 
prevention of lung inflammation. Although this study validated our observation about the antichlamydial 
effect of luteolin, it simultaneously demonstrated the poor correlation between the in vitro and in vivo 
experiments for quercetin and octyl gallate.    
 
Structural comparisons between active and inactive compounds enabled detection of some structural 
characteristics that differentiated these compounds in some compound groups. Flavones and flavonols 
have the same basic structure, and both groups contain active and inactive compounds. In these 
compound groups, structure is related to activity in such a way that all the compounds with 50% or less 
inhibition contain a sugar moiety or moieties as substituents, whereas none of the more active 
compounds (over 70% inhibition) contain sugars.  
 
8.1.2 Development of a new screening assay for C. pneumoniae (II)   
 
Conventional immunofluorescence staining (IF staining) is a widely used method in C. pneumoniae 
research, but it is unsuitable for the screening of even medium-sized compound libraries. We set out to 
develop a new cell-based assay that could be automated and used in the 96-well format. This new assay, 
named time-resolved fluorometric immunoassay (TR-FIA), is based on time-resolved fluorometry. TR-
FIA utilizes eurobium-conjugated antibody, which enables reliable separation between labeled C. 
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pneumoniae particles and the background, since eurobium label has a considerably longer half-life than 
normal (background) fluorescence (Soini and Kojola, 1983).     
 
The optimal conditions for TR-FIA were defined in accordance with Zhang et al (Zhang et al., 1999), 
using statistical parameters such as the signal-to-background (S/B) ratio, the signal-to-noise (S/N) ratio, 
and the screening window coefficient calculated from control sample data (Z’ factor). The S/B ratio 
measures the separation between the signal and the background, whereas the S/N ratio also takes into 
account information regarding data variation. The Z’ factor measures the ratio between the signal 
window and the dynamic range of the signal and is widely used to assess the quality of an assay for 
high-throughput screening. These three parameters were used to optimize the most critical factors of the 
new assay, namely antibody concentration, incubation time, and C. pneumoniae concentration. 
Comparison of the TR-FIA results to the IF staining and q-PCR was used to define the reliability of the 
assay.     
 
After optimization, the repeatability of TR-FIA was very good compared to other cell-based assays. 
Plate-to-plate variation was only 8.9% (n=3) and day-to-day variation 9.0% (n=3). In addition, when 
optimized conditions were used, the statistical parameters S/B, S/N, and Z’ were satisfactory for a cell-
based assay (6.46, 6.85, and 0.39, respectively). 
 
 
In general, the results obtained with TR-FIA were similar to the results of IF staining and q-PCR assay 
(Table 3 in II), but q-PCR occasionally gave slightly lower MIC values than TR-FIA or IF staining. 
This can be explained by the more sensitive nature of the PCR technology, which enables it to react 
faster to the decreasing number of C. pneumoniae particles. When the size of inclusions is decreased 
prior to total inhibition, as in the case of ciprofloxacin (Hammerschlag et al., 1992a), TR-FIA is also 
able to detect this decrease. Besides these small differences, the only significant exception was seen for 
penicillin, which gave a clearly lower MIC value with q-PCR than TR-FIA or IF staining. This 
difference can be explained by penicillin’s mechanism of action, which is unique among the 
antimicrobial agents used in this study. Penicillin blocks peptiglycan synthesis, which in C. pneumoniae 
is related to chlamydial cell division (McCoy et al., 2003) and possibly the conversion of EBs from RBs 
at the end of the development cycle (Chopra et al., 1998). This being the case, penicillin reduces the 
number of chlamydial particles inside the inclusions, which would be seen as inhibition in q-PCR, but 
does not reduce the number of inclusions, which means that no reduction can be seen in IF staining. 
Furthermore, the blockage of RB binary fission results in abnormally large RBs (Matsumoto and 
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Manire, 1970), which contain more lipopolysaccharide, the antigen of IF staining, and TR-FIA antibody. 
This explains why TR-FIA does not detect the reduction of the chlamydia particles.  
In conclusion, it can be said that TR-FIA gives reliable and reproducible results and is an excellent tool 
for the purpose it was designed for, i.e. primary screening of new antichlamydial compounds.      
 
8.1.3 Synthetic compounds (III) 
In addition to natural compounds, we also wanted to search for antichlamydial agents among synthetic 
compounds. Overall, synthetic libraries are large, and synthetic compounds have less biological activity 
than natural or natural-based compounds, but on the good side, individual synthetic compounds are 
cheaper and much easier to produce.  
 
Since we lacked the resources to screen large compound libraries, we decided to create a targeted library 
by virtually screening molecules that show affinity to the 3D structure of a selected C. pneumoniae 
target protein. The only problem in this case was that there are no publicly available 3D structures for 
any C. pneumoniae proteins. We tried to solve this problem by utilizing the inability of virtual 
screenings to reliably discriminate ligand binding between closely related protein isoforms (Schapira et 
al., 2003). We wanted to find the 3D structure of a close homolog of the C. pneumoniae target protein 
and to use it to screen molecules that would be more likely to bind to the actual C. pneumoniae target. In 
this way we could create a targeted library and reduce the number of molecules in the C. pneumoniae 
assay, without actually doing the time-consuming and expensive crystallization of the target protein.  
 
 
We started to search databases in order to find the C. pneumoniae target protein and a closely related 
non-human protein with a crystallized 3D structure and a highly similar active site area. We did not 
create a comparative model for the C. pneumoniae target protein, since we wanted to see if a high level 
of similarity in the amino acid sequence, and especially the binding pocket, is enough to guide the 
creation of a small library of active compounds. Extensive data mining produced a promising target-
homolog pair. The target was C. pneumoniae dimethyladenosine transferase (coded by the ksgA gene) 
and the crystallized homolog Staphylococcus aureus rna methyltransferase (coded by the ermC gene), 
which causes antibiotic resistance in many bacteria (but not in C. pneumoniae). These 
methyltransferases have highly similar active sites (Table 2 in III), and they bind their ligands in a 
similar way (Seppälä et al., 1998). In addition, in the International Union of Biochemistry and Molecular 
Biology (NC-IUBMB) classification, they belong to the same subclass: rRNA (adenine-N6-)-
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methyltransferase (EC: 2.1.1.48), whose indispensable functions are related to ribosomal structure and 
ribosomal methylation.  
 
The 3D structure of S. aureus RNA methyltransferase was used to virtually screen for a compound from 
two large Internet databases. These commercial databases, Specs (Delft, Netherlands: 
http://www.specs.net/) and Maybridge (Cornwall, England: http://www.maybridge.com/), contained 
over 300 000 molecules, and they were screened in silico in order to create a small targeted library, 
which should be highly active against C. pneumoniae. After the screening process, the 2000 best binding 
molecules, as ranked by the FlexX program, were analyzed visually, and 33 molecules were purchased 
and their anti-chlamydial properties were tested using TR-FIA (Fig. 5).  
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Figure 5. The most effective anti-chlamydial synthetic compounds. 
 
 
Eight out of the 33 tested compounds produced over 50% inhibition at 50 μM concentration. This 
activity percentage (24.2%) is extremely high compared to random libraries in general (Zolli-Juran et 
al., 2003), (Lewis et al., 2004), (Carey et al., 2004), and (Pilger et al., 2004). In the screening of a 
natural and natural-based compound library (I), 35 out of 57 compounds (61.4%) produced over 50% 
inhibition at the same concentration. Hence, although the virtual screening with the 3D structure of a 
close homolog increased the activity percentage of a synthetic compound library considerably, it was 
still not as high as in natural-based libraries. Even if the actual 3D structure of the target protein were 
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used in the creation of a targeted library, it would hardly be more – or even equally – active compared to 
a nature-originated library, where evolution has selected the molecules that can destroy a variety of 
microorganism.  
 
8.2 Host cell response to C. pneumoniae infection (IV, V)   
In this part of the study, we used genomics and proteomics in order to define the host cell response to C. 
pneumoniae infection. In gene expression studies, we utilized human microarrays which contained more 
than 22 000 human genes and measured the changes in the host cell gene expression from the C. 
pneumoniae infected HL cell line at four different time points p.i. The microarray data was used to select 
new potential drug targets for C. pneumoniae, and the most promising target genes were evaluated by 
silencing their expression with gene-specific siRNA molecules and monitoring the effect of this 
treatment on the C. pneumoniae infection.  
 
In proteomics studies, we compared the protein profile of infected cells to that of uninfected controls by 
labeling the proteins from the infected and control cells with different label and identified the proteins 
whose expression was altered because of the infection.  
 
8.2.1 Interpretation of gene expression data (IV) 
C. pneumoniae infection causes significant changes in host cell gene expression throughout the entire 72 
h development cycle. The majority of these changes take place at the early stage of the infection. In the 
middle part of the cycle, gene expression seems to normalize after C. pneumoniae has hidden inside the 
inclusion in the host cell cytoplasm, but it increases again at the end of the cycle, when the host cell is 
broken down. The gene expression changes that we observed were due to two different reasons; 
activation of the host cell defense systems and conscious control of the host cell gene expression by C. 
pneumoniae. When new drug targets are identified, discrimination between these two is paramount, but 
not necessarily easy. There are genes that are directly linked to the host cell defense systems, and their 
over-expression is part of the cell defense system, but the majority of genes could theoretically be 
beneficial or harmful to the infection.  
 
 
The microarray results from four time points (12 h, 24 h, 48 h, and 72 h) were compared against each 
other in order to characterize the host cell response at the different stages of the infection. In order to 
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facilitate the identification of genes related to harmful phenomena, we used the gene ontology (GO) 
classification (Ashburner et al., 2000). This classification system groups genes in terms of their 
associations with different biological processes, cellular components, or molecular functions. A 
biological process describes a biological goal, which is achieved through one or more assemblies of 
molecular function. Cellular component describes locations at the levels of subcellular structures and 
macromolecular complexes. Molecular function describes molecular level activities (Harris et al., 2004). 
A gene can be annotated to any number of ontologies, and annotation to one ontology is independent of 
its annotation to other ontologies. Currently, there are 5978 different GO terms in the gene ontology 
database. 
 
The use of GO terms enabled us to discover broader phenomena than just changes in the expression of 
individual genes. We used a p-value of 0.01 to identify significantly affected GO terms from the GO-
classified data. In this case, p-value measured the probability that the changes in gene expression of all 
genes belonging to a single GO term at one time point, compared to the average gene expression values 
of corresponding genes at three other time points, is coincidental. Table 6 contains a collection of the 
interesting GO terms that were significantly affected by C. pneumoniae infection.  
 
With GO annotation, we were able to find phenomena that are already linked to C. trachomatis 
infection, such as Ca2+ ion homeostasis (Majeed et al., 1993), glycogen synthesis (Weigent and Jenkin, 
1978), Wnt pathway (Prozialeck et al., 2002), hormone receptor activity (Kaushic et al., 2000), 
prevention of MHC expression (Zhong et al., 2001), and different effects on vesicle transport systems 
(Hackstadt et al., 1995). In addition, it has been shown in C. psittaci that the host cell’s energy 
production is accelerated by infection (Ojcius et al., 1998), and we observed the same phenomenon 
concerning increased ATP production and glutamate metabolism. Furthermore, some of the phenomena 
that we discovered using the GO classification have already been reported to be affected by C. 
pneumonia infection, such as the effects on growth factors (Prochnau et al., 2004) and the changes in 
host cell phosphorylation (Krull et al., 2004). We were also able to find new host cell phenomena not 
previously known to be affected by C. pneumonia infection, such as chaperone regulator activity, amino 
acid derivative catabolism, and subtilase activity. In addition, we also obtained more detailed 
information about the potential mechanisms of action of the discovered phenomena, such as Ca2+ ion 
influence through the troponin complex. 
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Table 6. The most interesting significantly affected GO terms at the different stages of the infection. 
Complete underlining of the GO term reflects a positive collective change on the genes of that GO term, 
no underlining reflects a negative change, and underlining of the GO term with a broken line means that 
about half of the genes of that term were down- and the other half up-regulated. The changes were 
defined by looking at the gene graphs in the R program. 
 
12 h 24 h 48 h 72 h 
Exocyst Troponin complex Exocyst 
Histone 
acetyltransferase 
activity 
Clathrin coat of trans-
Golgi network vesicle
cGMP-specific 
phosphodiesterase 
activity 
Subtilase activity Amino acid transporter activity 
v-SNARE activity Fructose-bisphosphate aldolase activity
Lipid phosphatase 
activity 
Insulin-like growth 
factor binding 
ATPase stimulator 
activity 
Calcium channel 
regulator activity Response to toxin Growth factor binding 
Insulin-like growth 
factor binding Citrate metabolism Sterol biosynthesis 
Antigen processing, 
endogenous antigen 
via MHC class I 
Steroid hormone 
receptor activity
Amino acid derivative 
catabolism 
Xenobiotic 
metabolism 
Negative regulation of 
Wnt receptor signaling 
pathway 
Chaperone regulator 
activity 
Neurotransmitter 
catabolism  Lipid catabolism 
Sphingomyelin 
phosphodiesterase 
activity 
   
Ligand-dependent 
nuclear receptor 
activity
   
Negative regulation of 
Wnt receptor signaling 
pathway
   
Glycogen catabolism    
Protein targeting to 
vacuole    
DNA modification    
 
8.2.2 Selection of potential drug target genes (IV) 
 
 At the first stage, we tried to identify up-regulated GO terms among the significantly affected GO terms 
at the 12 h time point. These terms were assumed to be essential for C.  pneumoniae infection, but not 
for the host cell. GO terms from the 12 h time point were emphasized in the selection process, since 
prevention of the onset of the infection would eliminate the possible development of chronic infection at 
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the later stages of the development cycle. Up-regulation was a prerequisite, since we were going to use 
gene silencing in the target validation process. At the next stage, we identified the individual genes 
which were mainly responsible for the up-regulation of these GO terms and selected them as target 
genes. Based on the GO data, we selected a total of five genes as potential targets: CYR61, DKK1, 
NR4A1, PYG, and V-FOS.  
 
The use of GO terms gives undoubtedly more information about the C. pneumoniae – host cell 
interaction than the expression changes of individual genes. On the other hand, genes that are 
responsible for the significant effect of a GO term are not necessarily the ones with the largest changes 
in their expression, when gene expression changes are compared between infected and non-infected 
cells. The reason for this is that, in the GO classification, the GO terms must be compared against each 
other at different time points and not against uninfected control. Thus, another set of target genes was 
selected using gene-wise analysis data, where data from infected cells were compared against control 
cell data. In this process, individual genes were ranked based on the changes in their expression rate. 
The genes that showed highest up-regulation by the C. pneumoniae infection at the 12 h time point and 
were potentially important for the survival of the infection, were also selected as target genes. A total of 
six genes (ACHE, EMP1, EGR1, FLJ23356, FLJ32065, and IGFBP1) were selected as target genes 
based on the gene-wise analysis.     
8.2.3 Drug target validation (IV) 
The gene expression changes of all selected drug targets were confirmed by using q-PCR (Table 3 in 
IV), and based on the results, the following genes were considered to be validated; CYR61, DKK1, 
EGR1, IGFBP1, NR4A1, and V-FOS. The validation process showed that the target genes selected 
based on the GO data were more reliable, since four out of five genes could be validated, whereas only 
two of the six genes selected using gene-wise analysis showed similar expression in q-PCR and 
microarray. 
  
 
The validated genes that were selected using GO data have a variety of functions. The CYR61 gene 
belongs to the GO term ‘Insulin-like growth factor binding’, and its expression is regulated by the Wnt 
signaling pathway (Si et al., 2006), which we found to be considerably affected at the different stages of 
the infection. The DKK1 gene belongs to GO term ’Negative regulation of the Wnt receptor signaling 
pathway’, and it was selected as a target gene, to further investigate the significance of the Wnt-
signaling pathway for C. pneumoniae infection. Several steroid-related GO terms were altered 
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throughout the infection (partially shown in table 6), and the NR4A1 gene was selected as a target gene, 
since it was the most up-regulated gene at the 12 h time point in the ‘Steroid hormone receptor activity’ 
GO term. The V-FOS gene was selected as a target gene in order to evaluate the effect of DNA 
modification on C. pneumoniae infection.  
 
Both of the genes that were selected using gene-wise analysis are related to growth factors. The EGR1 
gene codes a transcription factor with a C2H2 type zinc finger (Sukhatme et al., 1988). It is normally 
induced by growth factors and causes expression of the genes required for cell differentiation and 
mitogenesis. This gene has previously been shown to be activated by C. pneumoniae infection (Bea et 
al., 2003), and it is speculated to be involved in the regulation of proatherosclerotic factors that 
contribute to the pathogenesis of atherosclerosis (Rupp and Maass, 2003). The IGFBP1 gene is an 
insulin-like growth factor binding protein (Shimasaki and Ling, 1991), which has potential to modulate 
the antiapoptotic effect and to regulate cell proliferation (Firth and Baxter, 2002). This family of insulin-
like growth factor binding proteins might have an important role in C. pneumoniae infection, since the 
other members of this family are affected during persistent infection (Mannonen et al., 2007).    
 
8.2.4 Effect of target gene silencing on C. pneumoniae infection (IV) 
In order to evaluate the effect of target genes on C. pneumoniae infection, two corresponding siRNA 
molecules were tested for each target, and the silencing effect was monitored with q-PCR (Table 4 in 
IV). The siRNA molecule that lowered gene expression most was used in further experiments. The 
effect of siRNA molecules on C. pneumoniae infection was evaluated using TR-FIA (Fig. 6). Each of 
the target genes was silenced in the HL cell line by transfecting cells with corresponding siRNA and 
infecting them with C. pneumoniae 16h after transfection. The cytotoxic effect of siRNA molecules was 
also evaluated in order to see whether the silenced genes are suitable for drug targets (Fig. 6). In this 
way we were also able to confirm that the possible reduction in the number of C. pneumoniae inclusions 
was not due to the cytotoxicity of the siRNA molecules used. 
 
 
All siRNA molecules were able to reduce the number of C. pneumoniae particles, but they also caused a 
small reduction in the number of viable cells. The decreased number of HL cell can explain the smaller 
number of C. pneumoniae particles for some of the siRNAs, such as NR4A1, DKK1, IGFBP1, and 
possibly V-FOS, but not all of them. EGR1 and CYR61 clearly cause the reduction for some other 
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reasons. These genes are “immediate early genes”, which means that they response fast to an appropriate 
stimulus.  
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Figure 6. Effect of siRNA molecules on the number of C. pneumoniae particles (black bars) and the 
number of viable HL cells (white bars). Percentage values were calculated from three replicates.  
 
 
EGR1 encoded a transcription factor is activated by a variety of signals, including serum, growth 
factors, cytokines, and hormones. It is related to diverse cellular functions, such as cell proliferation, 
differentiation, and apoptosis (Gashler and Sukhatme, 1995). Based on these experiments, it is 
impossible to say whether the overall growth-stimulating effect or an as yet unidentified protein whose 
expression is controlled by this transcription factor makes this gene important for C. pneumoniae 
infection. EGR-1 siRNA silenced the expression of the EGR-1 gene rather poorly (Table 4 in IV), 
which indicates that activation of this gene might be even more important for the survival of C. 
pneumoniae infection than is suggested by these experiments.  
 
 
The CYR61 encodes a cysteine-rich protein, which is normally induced by growth factors (Lau and 
Nathans, 1985). This protein is secreted out of the cell, where it binds to heparin and promotes the 
adhesion of endothelial cells through integrin interaction. It is also capable of promoting angiogenesis 
and tumor growth (Babic et al., 1998). It is known that C. pneumonia (Wuppermann et al., 2001) and C. 
trachomatis (Zhang and Stephens, 1992) attachment to eukaryotic cells is dependent upon the presence 
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of a heparan sulfate-like ligands on the cell surface, and since the siRNA molecule that silences this 
gene reduced the number of C. pneumonia particles considerably, this protein might promote the 
attachment of extracellular chlamydia particles to the membranes of surrounding cells. On the other 
hand, CYR61 is annotated to the GO term ’Insulin-like growth factor binding’, and several members of 
the insulin-like growth factor binding protein family are known to be affected by infection through an 
unknown mechanism (Lin et al., 2001) (Ren et al., 2003) (Xia et al., 2003). Further studies are therefore 
needed in order to define the role of CYR61 in chlamydia infection. 
 
8.2.5 Changes at protein level (V) 
C. pneumoniae infection caused significant changes in the host cell gene expression, and we wanted to 
see if the same happens at the protein level. Since changes at the protein level take longer time than 
those at the gene level, we isolated proteins only 48 h and 72 h p.i. We utilized two-dimensional 
difference gel electrophoresis (2D-DIGE) coupled with mass-spectrometric identification in order to 
investigate changes in the proteome of infected HL cells. The combination of separation and 
identification tools that we used enabled identification of 1270 spots at 48 h and 1040 spots at 72 h time 
points. At both time points, the same four host cell proteins were found to be differently expressed in 
response to C. pneumoniae infection (Table 2 in V). All these proteins; Keratin 8 (type II), Keratin 18 
(type I), Vimentin, and β-tubulin, are structural components of the cytoskeleton. This seems compatible 
with the already established finding that rearrangement of the host cell cytoskeleton has an essential role 
in chlamydia infection (Schramm and Wyrick, 1995) (Wissel et al., 2003).    
 
None of the genes coding for the four proteins whose expression  was changed significantly by the C. 
pneumoniae infection showed significant changes in their expression in the microarray experiment. This 
can be explained by the fact that all of the differently expressed proteins were observed to have different 
Mr and/or pI values in 2D-gel than they should have in theory. This is normally an indication of post-
translational modification, and 2D-DIGE and MALDI-TOF analyses were able to show that these 
proteins have undergone post-translational modification during the infection. This is not surprising since 
it is known that tyrosine phosphorylation of host cell proteins takes place at the beginning of C. 
trachomatis infection (Birkelund et al., 1997).    
 
 
Although gene expression experiments with microchips were able to identify hundreds of genes whose 
expression was changed dramatically by infection, no change in the corresponding proteins could be 
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detected in the proteomics experiment. For some proteins, this lack of correlation may be due to the long 
turnover rate of the protein or some control mechanism that prevents protein translation, but for the most 
part it is due to the overall lower sensitivity of the protein separation and identification methods (Tian et 
al., 2004). This lower sensitivity of the proteomics tools can be seen in the number of identified spots. 
Although there must be tens of thousands of different proteins and their modifications in cells, we were 
able to separate and identify only about 1000 spots. In addition, only one C. pneumoniae protein (the 
major outer membrane protein; MOMP) could be identified from the 2D-gel.       
 
The proteins that were found to be affected by the C. pneumoniae infection in this study were assumed 
to be unsuitable as drug targets for two reasons: Firstly, they were all products of post-translational 
modification, and the native forms they were derived from were not affected by the infection, and 
secondly, all of these proteins are structural elements of the cytoskeleton, and their disturbance would 
probably have destructive consequences for the host cell.    
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9 CONCLUSIONS 
 
Natural products are known to exhibit a high level of antibacterial activity. A library of structurally 
diverse natural compounds (and their derivates) from one of the most active groups, flavonoids, was 
tested against C. pneumoniae. These plant phytoalexins are already known to have a variety of health-
promoting effects in humans, and the results of this study revealed one additional effect, namely their 
extremely high activity against a common human pathogen, C. pneumonia. In addition to nature-based 
compounds, antichlamydial activity was also searched for among synthetic compounds. In order to avoid 
a massive screening project, synthetic compounds were pre-screened in silico. This virtual screening was 
done using a structural homolog of the selected C. pneumoniae target protein. The results of the virtual 
screening experiment were used to construct a small targeted library. This library was purchased and 
tested against C. pneumoniae, and it demonstrated clearly higher activity than synthetic libraries in 
general, and although it was not as active as the nature-based library, these compounds provided 
excellent leads for further synthesis.   
 
The development of a new high-throughput screening system (TR-FIA) for the primary screening of 
new antichlamydial compounds was one of the aims of this study. The biggest problem in the 
development of this cell-based assay, the high background value, was resolved by using time-resolved 
fluorescence label, which can be measured after the background fluorescence has faded away. After the 
optimization of this partly automated 96-well plate assay, results were reliable, reproducible, and 
consistent with the two assays mostly used in chlamydia susceptibility testing, IF staining and q-PCR.    
 
 
 Defining the host cell response to C. pneumoniae infection and identification of potential drug targets 
was one of the central purposes of this study. This response was monitored at the gene and protein 
levels. At the genome level we were able to identify hundreds of genes that were significantly affected 
by infection. Genes were grouped according to biological processes, cellular components, and molecular 
functions in order to elicit more information out of the data. This GO classification approach compares 
the changes in gene expression at the different stages of infection and gives more reliability to the data, 
since it is not based on the expression changes of a single gene. A group of genes was selected as 
potential drug target genes based on this classification system, and another group was selected based on 
gene-wise analysis, where an infected sample is compared against an uninfected control at a single time 
point. The expression changes of all target genes were confirmed with q-PCR, the validated genes were 
silenced with corresponding siRNA molecules, and the effect of silencing on C. pneumonia infection 
was monitored using TR-FIA. The more reliable nature of GO data was evident in the validation 
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process, where four out of five target genes from the GO data could be validated, whereas only two of 
the six genes that were selected from gene-wise analysis data passed q-PCR validation. The GO 
classification provided an excellent way to elucidate the C. pneumonia infection process, but further 
research is needed to link these discovered phenomena unquestionably to the C. pneumonia infection 
process. Silencing of the six potential target genes revealed two genes, EGR1 (selected based on gene-
wise analysis) and CYR61 (selected based on GO analysis), whose silencing reduced the number of C. 
pneumonia particles considerably without significantly reducing the viability of the host cells. 
 
Although the changes at the protein level are more relevant to cell function, the protein monitoring tools 
are less sensitive than the tool used to study gene expression, which became evident during this study. 
We were able to find only four different host cell proteins with significant differences in their expression 
because of C. pneumoniae infection. All these proteins were structural proteins, which supports the 
earlier observations about the structural rearrangements required for a successful chlamydia infection, 
but at the same time makes them unsuitable as drug targets.  
 
The main achievements of this study, i.e. the utilization of the GO classification system in drug target 
identification and the design and construction of small focused libraries with high antichlamydial 
activity, can also be applied to other bacteria, enabling the development of new antimicrobial 
compounds against a variety of pathogens. 
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